1-deoxysphinganine promoted microglial glycolytic reprogramming and neuroinflammation in alzheimer's disease - PubMed
3 days ago
- #Neuroinflammation
- #Alzheimer's Disease
- #Metabolic Reprogramming
- 1-deoxysphinganine (deoxySO) levels are elevated in the serum of Alzheimer's disease (AD) patients and correlate with cognitive impairment.
- In APP/PS1 mice, deoxySO supplementation worsens cognitive deficits, increases Aβ plaque accumulation, and enhances microglial activation and inflammation.
- In vitro studies show deoxySO promotes glycolytic reprogramming in microglia, leading to disease-associated microglia (DAM) activation and neuroinflammation.
- Targeting deoxySO-mediated metabolic pathways may offer a novel therapeutic strategy for Alzheimer's disease.